CHICAGO--(BUSINESS WIRE)--SimBioSys, a technology company developing a first of its kind precision medicine platform, combining biophysical modeling and artificial intelligence, today announced the appointment of Anant Madabhushi, PhD and Donald Berry, PhD to its scientific advisory board (SAB).
Dr. Madabhushi is the Professor of Biomedical Engineering at Georgia Institute of Technology and Emory University. He is considered a global leader in developing artificial intelligence to improve outcomes for individuals. Prior to joining Emory University, Dr. Madabhushi was at Case Western Reserve University where he served the Case School of Engineering as the director of the Center for Computational Imaging and Personalized Diagnostics, and Donnell Institute Professor of Biomedical Engineering in the Department of Biomedical Engineering. With an impressive history, authoring over 400 peer-reviewed papers, and more than 100 patents, the expertise offered by Dr. Madabhushi is invaluable. In 2019, Nature Magazine named him one of the five scientists who are developing "offbeat and innovative approaches for cancer research." His work on "Smart Imaging Computers for identifying lung cancer patients who need chemotherapy" aligns with the revolutionary work SimBioSys is conducting with TumorScope and tumor imaging in breast cancer research and other disease areas.
On joining SimBioSys’ Advisory Board, Dr. Madabushi shares, "I have devoted my career to developing technologies in cancer research towards making an impact in patients' lives. SimBioSys aims to combine state of the art deep learning and mathematical modeling towards streamlining treatment planning decisions in a visual and explainable manner. I am excited to support the team’s journey towards this cause."
Dr. Berry founded both the Department of Biostatistics at the University of Texas M.D. Anderson Cancer Center (in 1999) and Berry Consultants, LLC (in 2001). He has held endowed chairs at M.D. Anderson and Duke University. He is recognized globally for his development of statistical theory and methodology as well as for having designed and supervised hundreds of innovative clinical trials. Dr. Berry ranks among the top one percent of the most cited researchers in Clinical Medicine according to Thomson Reuters. His application of Bayesian analysis to cancer clinical trials has minimized the necessary sample size for a clinical trial while increasing the prospect of detecting therapeutic activity. SimBioSys’ clinical design and evidence development have been significantly impacted by his world-renowned statistical expertise. In only a couple months, Dr. Berry has profoundly influenced product development, regulatory submissions, and clinical trial design for a number of SimBioSys’ applications. He will continue to help innovate SimBioSys’ evidence generation.
Dr. Berry has been closely involved in numerous breast cancer innovations, such as SimBioSys first indication, including designing and serving as the co-PI of I-SPY 2. He shares, “There is a significant unmet need for upfront markers beyond traditional methods to right-size therapy based on early patient-level information of treatment effect. I am excited to support SimBioSys’ clinical evidence generation and trial design in support of its mission.”
Both Dr. Madabhushi and Dr. Berry will help SimBioSys continue to expand its already vibrant communication channels among research communities. So far this year, SimBioSys has presented seventeen abstracts and posters at international medical and scientific conferences and continues to share new research and innovate at a rapid pace.
About SimBioSys
SimBioSys is a technology company deploying a combination of artificial intelligence and biophysical simulations to improve our understanding of cancer. By virtualizing cancer, SimBioSys aims to empower clinicians and patients with a better understanding of the disease and ability to assess all available options computationally to truly individualize treatment.